drug_type
RELEVANT_DRUG
intervention_type
Biological (trispecific T-cell engager)
drug_description
A trispecific T-cell engager (TriTE) given intravenously that binds CD19 on B cells, CD3 on T cells, and CD28 for co-stimulation, bridging T and B cells to trigger TCR activation and co-stimulation, leading to targeted cytotoxicity and depletion of CD19+ B cells/plasmablasts to reduce autoantibody production; carries cytokine release syndrome risk mitigated by a low priming dose.
nci_thesaurus_concept_id
C201656
nci_thesaurus_definition
A trispecific T-cell engager and antibody targeting the tumor-associated antigen (TAA) CD19, the T-cell surface antigen CD3, and the T-cell specific surface glycoprotein and co-stimulatory molecule CD28, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD19/anti-CD3/anti-CD28 trispecific antibody CC312 targets and binds to CD3 and CD28 on T-cells and CD19 expressed on tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen overexpressed in B-cell lineage malignancies.
drug_category
TRISPECIFIC T ENGAGER
drug_class
Engager
drug_delivery_route
Intravenous
drug_mechanism_of_action
Trispecific antibody that binds CD19 on B cells and CD3 plus CD28 on T cells, bridging T and B cells to provide TCR activation with CD28 co-stimulation, triggering T-cell–mediated cytotoxicity and depletion of CD19+ B cells/plasmablasts.
drug_name
CC312
nct_id_drug_ref
NCT06888960